Skip to content

Study · Animal study (in vivo) · mouse · 2024

6 results

Fertility protection during chemotherapy treatment by boosting the NAD(P)+ metabolome.

Ho WJ, Marinova MB, Listijono DR, Bertoldo MJ, Richani D, Kim LJ, Brown A, Riepsamen AH, Cabot S, Frost ER, Bustamante S, Zhong L and 14 more

Show all authors

Selesniemi K, Wong D, Madawala R, Marchante M, Goss DM, Li C, Araki T, Livingston DJ, Turner N, Sinclair DA, Walters KA, Homer HA, Gilchrist RB, Wu LE

EMBO molecular medicine21 Aug 2024Cited by 13 (Europe PMC)

PMID39169162 (opens in a new tab)PMCIDPMC11473878 (opens in a new tab)DOI10.1038/s44321-024-00119-w (opens in a new tab)PepBankPUB-39169162
Download PDFPubMedAsk about this study
Jump to 6 results

Summary

Chemotherapy induced ovarian failure and infertility is an important concern in female cancer patients of reproductive age or younger, and non-invasive, pharmacological approaches to maintain ovarian function are urgently needed. Given the role of reduced nicotinamide adenine dinucleotide phosphate (NADPH) as an essential cofactor for drug detoxification, we sought to test whether boosting the NAD(P)+ metabolome could protect ovarian function. We show that pharmacological or transgenic strategies to replenish the NAD+ metabolome ameliorates chemotherapy induced female infertility in mice, as measured by oocyte yield, follicle health, and functional breeding trials. Importantly, treatment of a triple-negative breast cancer mouse model with the NAD+ precursor nicotinamide mononucleotide (NMN) reduced tumour growth and did not impair the efficacy of chemotherapy drugs in vivo or in diverse cancer cell lines. Overall, these findings raise the possibility that NAD+ precursors could be a non-invasive strategy for maintaining ovarian function in cancer patients, with potential benefits in cancer therapy.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study6

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In a triple-negative breast cancer mouse model, NMN reduced tumour growth.

    In plain wordsIn mice with triple-negative breast cancer, NMN reduced tumour growth.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    DecreaseTumour growth
    Study

    mousen: not reported in source

    triple-negative breast cancer mouse model
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Importantly, treatment of a triple-negative breast cancer mouse model with the NAD+ precursor nicotinamide mononucleotide (NMN) reduced tumour growth and did not impair the efficacy of chemotherapy drugs in vivo or in diverse cancer cell lines.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In a breast cancer mouse model, NMN did not impair chemotherapy drug efficacy.

    In plain wordsIn mice with breast cancer, NMN did not reduce chemotherapy effectiveness.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    No significant changeChemotherapy efficacy in vivo
    Study

    mousen: not reported in source

    triple-negative breast cancer mouse model
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Importantly, treatment of a triple-negative breast cancer mouse model with the NAD+ precursor nicotinamide mononucleotide (NMN) reduced tumour growth and did not impair the efficacy of chemotherapy drugs in vivo or in diverse cancer cell lines.
  3. 03LabIn vitro (cells)Efficacy outcome

    In diverse cancer cell lines, NMN did not impair chemotherapy drug efficacy.

    In plain wordsIn cells, NMN did not reduce chemotherapy effectiveness across diverse cancer cell lines.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    No significant changeChemotherapy efficacy in cancer cell lines
    Study

    n: not reported in source

    diverse cancer cell lines
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Importantly, treatment of a triple-negative breast cancer mouse model with the NAD+ precursor nicotinamide mononucleotide (NMN) reduced tumour growth and did not impair the efficacy of chemotherapy drugs in vivo or in diverse cancer cell lines.

Studies that did not test the peptide alone3

In this study, NMN (nicotinamide mononucleotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking NMN (nicotinamide mononucleotide).

  1. 04AnimalNot a test of NMN (nicotinamide mononucleotide) aloneAnimal study (in vivo)Efficacy outcome

    In mice, pharmacological or transgenic NAD replenishment strategies ameliorated chemotherapy-induced infertility as measured by oocyte yield.

    In plain wordsIn mice, pooled drug or gene strategies to restore NAD improved chemotherapy-related infertility measured through oocyte yield.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    Direction not reportedOocyte yield
    Study

    mousen: not reported in source

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health

    Source sentences

    Summary
    We show that pharmacological or transgenic strategies to replenish the NAD+ metabolome ameliorates chemotherapy induced female infertility in mice, as measured by oocyte yield, follicle health, and functional breeding trials.

    In this study, NMN (nicotinamide mononucleotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking NMN (nicotinamide mononucleotide).

  2. 05AnimalNot a test of NMN (nicotinamide mononucleotide) aloneAnimal study (in vivo)Efficacy outcome

    In mice, pharmacological or transgenic NAD replenishment strategies ameliorated chemotherapy-induced infertility as measured by follicle health.

    In plain wordsIn mice, pooled drug or gene strategies to restore NAD improved chemotherapy-related infertility measured through follicle health.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    Direction not reportedFollicle health
    Study

    mousen: not reported in source

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health

    Source sentences

    Summary
    We show that pharmacological or transgenic strategies to replenish the NAD+ metabolome ameliorates chemotherapy induced female infertility in mice, as measured by oocyte yield, follicle health, and functional breeding trials.

    In this study, NMN (nicotinamide mononucleotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking NMN (nicotinamide mononucleotide).

  3. 06AnimalNot a test of NMN (nicotinamide mononucleotide) aloneAnimal study (in vivo)Efficacy outcome

    In mice, pharmacological or transgenic NAD replenishment strategies ameliorated chemotherapy-induced infertility in functional breeding trials.

    In plain wordsIn mice, pooled drug or gene strategies to restore NAD improved chemotherapy-related infertility in breeding trials.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    Direction not reportedFunctional breeding trials
    Study

    mousen: not reported in source

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health

    Source sentences

    Summary
    We show that pharmacological or transgenic strategies to replenish the NAD+ metabolome ameliorates chemotherapy induced female infertility in mice, as measured by oocyte yield, follicle health, and functional breeding trials.

    In this study, NMN (nicotinamide mononucleotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking NMN (nicotinamide mononucleotide).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.